Background
The depletion of CD4 T cells is a hallmark of HIV-1 pathogenesis and AIDS progression [1]. Multiple studies have attempted to explain the depletion of CD4 T cells during HIV-1 infection. This can be broadly categorized into killing of uninfected "bystander" CD4 T cells, and "direct" killing of HIV-infected CD4 T cells [2]. Interestingly, the rate of CD4 T cell decline is discordant with low level of productively infected cells in HIV-positive individuals. This suggests "direct" death of productively infected cells contributes minimally towards AIDS progression, and bystander cell killing appears to be the leading cause for CD4 T cell loss and AIDS progression [3]. The HIV-1 Env, also known as the gp120/gp41 glycoprotein, is expressed on the surface of infected cells or on HIV-1 virions and can interact with bystander cells expressing CD4. This interaction is critical for HIV-1 entry and has been proposed to induce bystander CD4 T cell death [4–6].

HIV-1 strains can be broadly divided into two groups based on their Env tropism, each using CCR5 or CXCR4 chemokine co-receptor for viral entry. The CCR5-tropic HIV-1 Env interacts with CD4 and CCR5, infects CCR5+ CD4 T cells and macrophages, and is sensitive to CCR5 antagonists such as TAK-779. Likewise, the CXCR4-tropic virus interacts with CD4 and CXCR4, infects CXCR4+ CD4 T cells, and is sensitive to CXCR4

Keywords: CCR5, HIV-1 pathogenesis, HIV-1 Env, Bystander CD4 T cells, Humanized mice
antagonists such as AMD-3100 [7, 8]. In addition, dual-tropic HIV-1 strains have been reported that are capable to utilize both CCR5 and CXCR4 for entry [9–12]. R5-tropic HIV-1 dominates during the early stages of HIV-1 infection. In later stages of infection, X4-tropic viruses emerge and are thought to be responsible for the accelerated decline of CD4 T cells and AIDS progression [13]. The highly pathogenic phenotype of late stage X4-viruses has been related to the abundant expression of CXCR4 in virtually all CD4 T cells, whereas CCR5-expressing CD4 T cells are mostly memory T cells [14]. However, in a significant proportion (>50 %) of AIDS patients, there is no co-receptor switch detected and their AIDS-associated viruses are exclusively R5-tropic [15, 16]. Therefore, CCR5-tropic HIV-1 viruses can lead to AIDS progression but the mechanism remains unclear.

Previous reports have studied the pathogenic effect of HIV-1 Env binding to CCR5 by overexpression of R5-tropic Env on cell surface or by using recombinant R5-tropic gp120 proteins [4, 5, 17]. However, the pathogenic effect of R5-tropic Env has not been studied in HIV-1 infection models, or directly compared to HIV-1 viral load. In this report, we studied the Env pathogenicity of a highly pathogenic dual-tropic HIV-1 strain (termed R3A) derived from a rapid progressor [9]. The Env gene of R3A is highly pathogenic and has been used for HIV-1 pathogenesis studies [9–11]. The interaction of the V3 region of R3A-Env with the co-receptors and its specificity for either CCR5 or CXCR4 has been elucidated in a previous study [8]. We took advantage of a mutant R3A strain termed R3A-5/6AA from the study, which has lost the ability to bind and utilize CCR5 but can still use CXCR4 for viral infection, therefore not affecting viral replication capability. Interestingly, the mutant R3A-5/6AA is substantially less pathogenic than the wild type R3A, as evidenced by the reduction of virus-mediated bystander CD4 T cells depletion. Supporting the functional relevance of CCR5 interaction by R3A-Env in CD4 T cells pathogenesis, we found that the inhibition of Env-CCR5 binding by CCR5 antagonistic drug TAK-779 reduced R3A-induced bystander CD4 T cells killing, whereas stimulation of the CCR5 receptor with agonistic drug MIP-1β increased the pathogenesis effect. We confirmed our findings in vivo using a humanized mouse model, and we observed reduced bystander pathogenesis of the mutant R3A-5/6AA compared to the wild type R3A infection in CD4 T cells in the blood, spleen and bone marrow. We provide the first evidence in two physiologically relevant HIV-1 infection models that shows CCR5 interaction with a dual-tropic HIV-1 Env plays a significant role in Env-induced depletion of bystander CD4 T cells.

**Results**

A highly pathogenic HIV-1 isolate R3A induces depletion of both productively infected cells and bystander CD4 T cells in activated PBMCs.

We used a primary activated PBMC culture infection model to study the pathogenesis of the highly pathogenic dual-tropic HIV-1 strain (termed R3A) on CD4 T cells. Briefly, freshly isolated PBMCs (peripheral blood mononuclear cells) were infected with an MOI of 0.01 for 3 h, followed by T cell stimulation with CD3/CD28 activation beads. The kinetics of virus-induced CD4 T cell depletion can be accurately monitored (Fig. 1a), as CD4 T cell percentages and numbers in R3A infected PBMCs gradually decreased over time (Fig. 1b). R3A pathogenesis was completely prevented by the fusion inhibitor T20, which effectively inhibited viral entry and replication as measured by intracellular HIV-1 p24 staining (Fig. 1c). Co-staining of intracellular p24 with a cell viability dye allowed us to analyze the percentage of dying cells in both productively infected and uninfected CD4 T cells (Fig. 1c). Compared to mock infection, we observed a significant higher percentage of dying cells in the p24(–) CD4 T cell populations at 6 days post R3A infection, therefore we termed it as bystander cell pathogenesis (Fig. 1d).

**CCR5 antagonist TAK-779 protects CD4 T cells from R3A-induced bystander CD4 T cell depletion**

Expression of R5-tropic HIV-1 Env proteins on cell surface could induce the depletion of neighboring SupT1 cells in a CCR5-dependent manner [5]. To investigate
a) Live CD3+ cells

b) CD4 T cell depletion

Mock

R3A

R3A + T20

Days post infection

%CD4 T cell survival relative to mock

Mock

R3A

R3A + T20

Days post infection

CD4 T cell numbers

C) CD3

CD8

Mock

Bystander cells p24(-)

Infected p24(+) cells

T20 treatment

Cell viability staining

D) p24(-) cells

Cell death %

R3A

R3A + T20

Mock

p = 0.0003

Mock

R3A

R3A + T20

mock
how CCR5 interaction during dual-tropic R3A infection contributes to CD4 T cell depletion, we treated R3A infected cells with the CCR5 antagonist TAK-779. TAK-779 is known to block HIV-1 Env interaction with CCR5 and inhibit the infections of CCR5-tropic viruses [18]. As the dual-tropic R3A can also utilize CXCR4 for infection, we found R3A replication in CD4 T cells wasn’t significantly affected by TAK-779 treatment, as measured by intracellular p24 staining or extracellular HIV-1 RT levels (Fig. 2a). Interestingly, CD4 T cell depletion was significantly reduced by TAK-779 treatment (Fig. 2b). Furthermore, TAK-779 significantly reduced (p24−) CD4 T cell death to near background levels (Fig. 2c, d). However, cell death of HIV-1 infected (p24+) CD4 T cells was not significantly affected by TAK-779 (Fig. 2c, d). This data indicates blocking R3A-Env interaction with CCR5 reduced the pathogenesis on bystander CD4 T cells.

The binding of HIV-1 Env to the other co-receptor, CXCR4, has also been implicated in Env-induced cell death [19]. We therefore tested how CXCR4 binding by R3A Env affects viral pathogenesis using AMD3100, a CXCR4 antagonist [20]. Unlike TAK-779, the blockage of CXCR4 usage by AMD3100 significantly reduced the entry and replication of R3A in PBMCs (Additional file 1: Fig S1a, b). As expected, the combined treatment of TAK-779 and AMD3100 completely inhibited R3A infection, similar to T20. This suggests the dual-tropic R3A, although capable of using either co-receptor for entry, relies more heavily on CXCR4 for replication in primary CD4 T cells. Although blocking CXCR4 usage by R3A also reduced CD4 T cell depletion (Additional file 1: Fig S1c), the interpretation here is difficult since virus replication was also significantly inhibited.

**Ablation of CCR5 usage reduces dual-tropic HIV-1 pathogenesis in PBMC infection**

Our results with CCR5 antagonist TAK-779 treatment suggest the interaction of R3A-Env with CCR5 receptor contributed to CD4 T cells depletion during R3A infection. To expand this finding, we used a genetic mutant of R3A that is incapable of binding to the CCR5 receptor. As published before [8], the R3A-5/6AA mutant (with two alanine substitutions in the 5th and 6th amino acids of Env V3 region) has lost its capability to infect CCR5-expressing cells but not CXCR4-expressing cells (Additional file 2: Fig. S2a). R3A-5/6AA could efficiently utilize CXCR4 for virus entry and replication. Accordingly, we observed the virus replication was not significantly affected by its ablation of CCR5 usage, as R3A-5/6AA replicated to wild type R3A viremia levels as measured by both intracellular p24 staining and extracellular HIV-1 genomic RNA levels (Fig. 3a; Additional file 2: Fig. S2b). We then compared the pathogenesis of wild-type R3A with R3A-5/6AA. As shown before, the highly pathogenic R3A can significantly deplete CD4 T cell levels, with 60 % depletion at 6 dpi and 90 % depletion at 10 dpi. Remarkably, ablation of CCR5 usage by the mutant R3A-5/6AA significantly reduced CD4 T cell pathogenesis, with only 10 % depletion at 6 dpi and 35 % depletion at 10 dpi (Fig. 3b, c). This indicates R3A-Env binding with CCR5 strongly contributed to Env-mediated CD4 T cell depletion. The reduced pathogenicity of R3A-5/6AA observed is not a consequence of reduced virus growth advantage, as R3A-5/6AA replicated to similar levels as R3A (Fig. 3a). As shown before, R3A infection reduced the viabilities of both p24(−) and p24(+) CD4 T cells (Fig. 1c). Interestingly, the ablation of CCR5 binding in R3A-5/6AA infection completely rescued death of p24(−) bystander CD4 T cells to background levels (Fig. 3d). The cell viability of p24(+) cells was not significantly different in R3A and R3A-5/6AA infection (Fig. 3d). Therefore, our data indicate R3A could efficiently deplete both bystander and infected CD4 T cells, whereas R3A-5/6AA only induced perceivable pathogenesis in productively infected CD4 T cells. The reduced pathogenicity of R3A-5/6AA infection seen in Fig. 3c was therefore due to reduced bystander cell death, a consequence of the loss of CCR5 binding capability by the Env mutant. We conclude R3A-induced bystander pathogenesis is dependent on the viral Env interaction with CCR5.

**CCR5 agonist MIP-1β enhances R3A-5/6AA pathogenesis to promote bystander CD4 T cell depletion**

MIP-1β is a CCR5-specific chemokine and agonist [21]. We investigated whether activation of CCR5 by MIP-1β could complement for the ablated Env-CCR5 interaction in R3A-5/6AA infection and therefore enhance bystander pathogenesis. We found MIP-1β treatment significantly
Fig. 3 Ablation of CCR5 usage reduces dual-tropic HIV-1 pathogenesis in PBMC infection. 

**a** Intracellular p24 staining and FACS analysis was used to quantify viral replication in infected PBMCs. Infected (p24+) CD4 T cell numbers were calculated by multiplying the percentage of (p24+) cells with total CD4 T cell numbers at each time point (left). RT-qPCR analysis of HIV-1 genomic RNA levels was used to measure extracellular viral replication of R3A and R3A-5/6AA in infected PBMCs (right). 

**b** Representative FACS Plots are presented showing CD4 and CD8 populations gated on live CD3(+) T cells in PBMC at 6 days post infection. HIV-1 fusion inhibitor T20 treatment was used as negative control. 

**c** Kinetics of CD4 T cell depletion by R3A versus R3A-5/6AA was analyzed as described in Fig. 1b. CD4 T cell survival are measured as %CD4 T cells in infected PBMCs relative to mock infection (top), or live CD4 T cell numbers (bottom) over time. 

**d** p24(−) and p24(+) CD4 T cell death in R3A and R3A-5/6AA infected PBMCs are quantified at 6 days post infection, as described in Fig. 1C. FACS plots (left) and graphical summary (Right) from a representative experiment are presented. Experimental results were repeated with PBMCs from 3 different blood donors. *p < 0.05
increased the death of p24(−) CD4 T cells in R3A-5/6AA infected PBMC cultures, without affecting the viability of p24(+) CD4 T cells (Fig. 4a, b). Accordingly, MIP-1β also decreased the CD4 T cell survival (Fig. 4c). We conclude MIP-1β binding to CCR5 could partly mimic R3A's Env interaction with CCR5 and increase bystander CD4 T cell depletion.

Ablation of CCR5 usage reduces pathogenesis of dual tropic HIV-1 in a humanized mouse model in vivo

To confirm that Env-CCR5 interaction contributes to HIV-1 bystander pathogenesis in a relevant HIV-1 infection model in vivo, we compared the infection and pathogenesis of R3A with R3A-5/6AA in the huHSC mice, a suitable small animal model to study HIV pathogenesis in vivo [22]. Similar to infected PBMC cultures, R3A-5/6AA replication was delayed initially at 1 week post infection but reached similar viremia levels as R3A at 2 and 3 weeks post infection as measured by HIV genomic RNA levels in the blood and intracellular p24 staining of CD4 T cells in the spleen (Fig. 5a). When analyzed at 3 weeks post infection, we found R3A-5/6AA was significantly less pathogenic than R3A in vivo, with reduced CD4 T cell depletion in the blood, spleen and bone marrow (Fig. 5b). Furthermore, R3A infection resulted in higher cell death of p24(−) CD4 T cells than R3A-5/6AA infection in vivo (Fig. 5c). The viability of infected p24(+) CD4 T cells was similar in R3A and R3A-5/6AA infection (Fig. 5c). These findings indicate R3A Env interaction with CCR5 induced bystander CD4 T cell pathogenesis in HIV-infected humanized mice.

Discussion

Multiple viral and host factors determine the variability in HIV-1 disease progression [17, 23–26]. Cellular tropism and receptor/co-receptor usage for viral entry are major factors influencing HIV pathogenesis. Despite extensive research, the exact mechanism of how those factors contribute to the gradual loss of CD4 T cells is still enigmatic. Bystander CD4 T cell death plays a major contribution towards AIDS progression. A recent report has revealed a mechanism for HIV-induced CD4 T cell depletion, which involves abortive non-productive HIV infection in resting CD4 T cells, followed by IFI16 activation and caspase-1 dependent pyroptosis [27–29]. Besides the abortive RT products in non-productively infected resting cells, several HIV-1 proteins have also been reported to contribute to the depletion of bystander (uninfected and non-productively infected) CD4 T cells, including the Env [4, 5, 17, 19], Vpr [30], Nef [31, 32] and Tat [33]. The Env protein is of specific interest in mediating AIDS progression, and has been implicated as an important cytopathic determinant of AIDS-associated CCR5-tropic viruses [34, 35]. CCR5 expression levels on cell surface correlate with increased host susceptibility to R5-tropic Env-induced apoptosis [5]. Interestingly, humanized mice engrafted with CCR5Δ32−/− donor cells supported HIV-1 replication with reduced CD4 T cell depletion [36]. It has been difficult to directly define the role of CCR5 interaction in HIV-induced CD4 T cell depletion because CCR5 interaction is required for the replication of CCR5-tropic HIV-1. Our findings using a dual-tropic HIV-1 confirmed that the interaction between CCR5 and HIV-1 Env is a critical determinant of bystander CD4 T cell depletion. The dual-tropic R3A virus is known to be highly pathogenic, depleting thymocytes through multiple mechanisms including fusion-induced apoptosis [10] and fusion-independent interferon-mediated mechanism [11]. In humanized mice, R3A infection caused rapid depletion of both infected and uninfected CD4 T cells [22, 37]. Using an Env mutant R3A-5/6AA that has lost interaction with CCR5, we were able to show that the ablation of CCR5 usage by the dual-tropic R3A virus effectively decreased viral pathogenicity on bystander CD4 T cells in activated PBMC cultures (Fig. 3) and in humanized mice (Fig. 5). Notably, ablation of CCR5 usage did not significantly affect the killing of productively infected CD4 T cells (Figs. 3d, 5c), corresponding with previous reports that the R3A Env fusion activity [10] and other HIV-1 proteins can promote death of directly infected cells [38, 39]. It is of note that the replication of mutant R3A-5/6AA was lower compared to R3A at early time points (Fig. 5a). The delayed replication peak may have contributed to the decreased pathogenicity of the mutant virus at early time points.

Signal transduction through Env-CCR5 interaction on bystander CD4 T cells may contribute to viral pathogenesis [17, 24]. Here we showed that CCR5 antagonist TAK-779 decreased R3A-induced bystander CD4 T cells depletion (Fig. 2), whereas CCR5 agonist MIP-1β increased bystander pathogenesis (Fig. 4), supporting a role for CCR5 stimulation/signaling in R3A pathogenesis. Mechanistically, HIV-1 Env binding to CCR5 induces a signaling cascade including calcium influx, Pyk2 phosphorylation and downstream activation of p38 MAPK pathway [40–42]. Using a p38 inhibitor, Li et al. has shown that CCR5 engagement by HIV-1 Env leads to p38 activation and Fas- and caspase-dependent cell death [43]. The signaling through CCR5 by the R3A Env and subsequent p38 activation, together with Env binding to CD4, may be involved in R3A induced bystander T cell killing. MIP-1β binds to CCR5 and is also known to similarly activate Pyk2 and p38 MAPK pathways [42, 44], which may mimic the Env-CCR5 interaction and contribute to bystander cell death, as shown in Fig. 4. In addition to CCR5, the interaction of CXCR4 with HIV-1
Env is also known to contribute to Env-mediated cell death [19]. Although treatment with CXCR4 antagonist AMD3100 decreased R3A pathogenesis, the interpretation in this study is difficult since AMD3100 also significantly inhibited R3A replication (Fig S1). Therefore, like most dual-tropic viruses, R3A relies more heavily on CXCR4 than CCR5 usage for infection in primary PBMC. It remains to be determined whether CXCR4 binding by R3A Env also contributes to CD4 T cell death during infection. Lastly, the cooperative engagement of R3A Env to both CCR5 and CXCR4 may result in stronger binding of the Env to CD4 T cells, which may directly affect Env-mediated cell death. Loss of CCR5 engagement in our studies may have resulted in a weaker
binding to CD4/CXCR4 and therefore a reduced Env pathogenicity. Accordingly, MIP-1β may have enhanced this Env-CXCR4 interaction and therefore contributing to the increased cell death.

In summary, we provide the first evidence in relevant infection models with a dual tropic HIV-1 that can efficiently infect primary human PBMC when its binding to CCR5 is blocked genetically or pharmacologically, demonstrating CCR5 interaction with dual-tropic HIV-1 Env played a significant role in Env-induced depletion of bystander CD4 T cells. Our findings suggest that drugs such as Maraviroc or gene therapy targeting CCR5 interaction with HIV gp120 can not only prevent R5-mediated HIV-1 entry, they can also reduce Env-mediated CD4 T cell depletion and AIDS disease progression.

Conclusion
We provide the first evidence in relevant infection models that shows CCR5 interaction with a dual-tropic HIV-1 Env played a significant role in Env-induced depletion of CD4 T cells.

Methods
Cell cultures
Total PBMCs were isolated from peripheral blood of healthy donors by Ficoll-Paque™ Plus (GE Healthcare) density gradient centrifugation and maintained in RPMI 1640 (Gibco) supplemented with 10 % FBS, 1X Antibiotic–Antimycotic (Invitrogen) and 1 µM l-glutamine. T cell activation in PBMCs were performed with CD3/CD28 activation beads (Miltenyi Biotech) and cultured at concentration of 0.5 × 10^6 cells/mL in the presence of IL-2 (20 U/mL). When indicated, PBMCs were treated with 10 µg/mL fusion inhibitor T20 (NIH AIDS Reagents Program) before infection and maintained throughout the experiment. TAK-779 and AMD3100 (NIH AIDS Reagents Program) were treated before infection and maintained in CCR5-expressing or CXCR4-expressing MAGI cells as previously described [45].

HIV-1 infection of PBMC cultures
Unless indicated otherwise, infections of PBMCs with R3A or R3A-5/6AA was performed by infecting 1 × 10^6 freshly isolated PBMCs with MOI of 0.01 (as titered in CXCR4-expressing MAGI cells) for 3 h at 37 °C in a total volume of 100 µL supplemented RPMI medium containing polybrene (8 µg/mL). At 3 h post infection, viral inoculum were washed with PBS, activated with CD3/CD28 activation beads as described above, and cultured at concentration of 0.5 × 10^6 cells/mL in the presence of IL-2 (20 U/mL). When indicated, PBMCs were treated with 10 µg/mL fusion inhibitor T20 (NIH AIDS Reagents Program) before infection and maintained throughout the experiment. TAK-779 and AMD3100 (NIH AIDS Reagents Program) were treated before infection at an IC90 dose of 5 and 2 µM respectively, as determined before in U373-CD4-CCR5/CXCR4 cells. Treatment with 200 ng/mL MIP-1β started at 3 h post infection and maintained.

Flow cytometry analysis
Aliquots of infected PBMC samples (~1E5 cells) were collected for analysis at the indicated time points post HIV-1 infection. Staining for cellular surface CD3, CD4, CD8 (BD Biosciences) and viability dye (LIVE/DEAD fixable yellow dead stain, Invitrogen) were performed in 2 % FBS. Intracellular staining was performed after surface antibody staining, with the use of Fixation/Permeabilization Solution Kit (BD Cytofix/Cytoperm™), followed by staining with antibodies targeting p24 (Beckman Coulter, #KC-57). Cells were fixed by 1 % paraformaldehyde and analyzed with Cyan ADP FACS machine (DAKO).
Live total cell numbers were counted by Guava EasyCytes after staining with viability dye. %CD4 T cells survived at a the time point were analyzed as live CD3(+) CD8(−) populations in PBMCs. Total live CD4 T cell numbers at a given time were calculated using the total cell numbers multiplied by %CD4 T cells in PBMCs. Total infected CD4 T cell numbers were calculated using total CD4 T cell number multiplied by %p24(+) in live CD3(+) CD8(−) cells.

**HIV-1 infection of humanized mice and analysis**

DKO-huHSC mice were constructed as previously reported [22]. DKO-huHSC mice were infected with HIV-1 at 4000 infectious units/mouse by intravenous injection. At termination, whole animal’s blood and lymphoid organs including spleen and bone marrow were harvested as described before [22]. Total lymphocytes were isolated from lymphoid organs and red blood cells were lysed with ACK buffer, and remaining cells were stained and fixed before flow cytometry analysis as described above.

**RT-qPCR analysis and HIV-1 reverse transcriptase activity analysis of viral load**

Viremia in supernatants from infected PBMC cultures or from blood plasma of infected humanized mice was analyzed by viral RNA extraction (QIAamp viral RNA mini kit, Qiagen), and analyzed by RT-qPCR (Taqman One-Step RT-qPCR Master Mix, ABI) using the following primers and probe targeting HIV-1 Gag region: 765gagF 5′-GGTGCAGAGCGTCACTATTAA-3′; 911gagR 5′-AGCTCCCTGTGTGCCCATA-A-3′; probe FAM-AAATTCGGTTAAGGCGAAAAAGA-QSY7 (TAMRA). HIV-1 RT activity was analyzed in the infected PBMC supernatant as described before in Lee MH et al., *J Clinical Microbiology*, 1987.

**Statistical analysis**

The significance of all comparisons was calculated by the use of a Student 2-tailed t test, and results were considered significant when \( p < 0.05 \).

---

**Additional files**

**Additional file 1: Figure S1.** CXCR4 antagonist AMD3100 inhibits R3A replication. a PBMCs were treated with the indicated drugs before infection with R3A, and viral infection efficiencies were measured by %p24+ cells with FACS analysis at 4 days post infection. AMD3100 (2µM) and TAK-779 (5µM) were used at >IC90 dose as determined before in U373-CD4-CXCR4/CXCR4 cells. b PBMCs were treated with AMD3100 before infection with R3A and maintained after infection. HIV-1 replication was measured by extracellular HIV-1 reverse transcriptase activity in the cell supernatant. c CD4 T cell depletion by R3A in the presence of AMD3100 was measured by FACS analysis. %CD4 T cells relative to mock infected PBMCs are presented.

**Additional file 2: Figure S2.** Similar infection levels by R3A and R3A-5/6AA in PBMCs. a Infectivity of R3A and R3A-5/6AA HIV-1 strain was measured in CR5-expressing (Top) or CXCR4-expressing (Bottom) U373 MAGi cells. Viral infectivity was presented as infectious units per ng of p24. b PBMCs were infected with 20ng p24 of R3A or R3A-5/6AA virus stock, and viral replication kinetics was analyzed by intracellular p24 staining.

**Authors’ contributions**

LT carried out most of the experiments and drafted the manuscript. LS and LT conceived and designed the study. HG performed and analyzed experiments in vivo in the humanized mouse model. JJ first established the PBMC infection system to study HIV-1 pathogenesis and discovered a potential role of CCR5. JH published the initial discovery of mutant R3A that cannot utilize CCR5 for entry. All authors read and approved the final manuscript.

**Author details**

1 Curriculum of Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3 Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4 Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

**Acknowledgements**

We would like to acknowledge Dr. Katrina M. Nolan (former student of Dr. James A. Hoxie, University of Pennsylvania) for the initial discovery of the R3A mutant and provided for use in this study.

**Competing interests**

The authors declare that they have no competing interests.

**Received: 5 January 2016 Accepted: 17 March 2016 Published online: 29 March 2016**
References

1. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Cell Death Dis. 2000;1:285–9.

2. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis. Cell Death Dis. 2010;1:e69.

3. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Rupecheit RM, Kupfer A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med. 1995;1:129–34.

4. Joshi A, Lee RTC, Mohl J, Sedano M, Khong WX, Ng OT, Maurer-Stroh S, Garg H. Genetic signatures of HIV-1 envelope-mediated bystander apoptosis. J Biol Chem. 2014;289:2497–514.

5. Joshi A, Nyakeriga AM, Ravi R, Garg H. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity. J Biol Chem. 2011;286:36404–13.

6. Ahf B, Robert-Heblom V, Devaux C, Biard-Piechaczyk M. Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology. 2004;1:12.

7. Laakso MM, Lee F-H, Haggarty B, Agrawal C, Nolan KM, Biscone M, Chadwick D, Ruprecht RM, Kupfer A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymphoid tissue. J Exp Med. 2010;203:1177–88.

8. Meissner EG, Zhang L, Jiang S, Su L. Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology. 2004;328:74–88.

9. Meissner EG, Zhang L, Jiang S, Su L. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the thymus. J Virol. 2006;80:11019–30.

10. Jack MJ, Zhang L, Jiang S, Su L. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the thymus. J Virol. 2006;80:11019–30.

11. Swaraman V, Zhang L, Su L. Type I interferon contributes to CD4+ T cell depletion induced by infection with HIV-1 in the human thymus. J Virol. 2011;85:9243–6.

12. Reszka-Blanco NJ, Sivaraman V, Zhang L, Su L. HIV-1 Env and Nef cooperatively contribute to pDCs activation via CD4-dependent mechanisms. J Virol. 2015;89:695–715.

13. Connor RL. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621–8.

14. Salazar-Gonzalez JF, Salazar MG, Keele BF, Leitman GH, Giorgi EE, Li H, Deckert JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Guffey MB, Bar KJ, Davis KL, Ochsman-Baucher J, Cappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Haber R, Perelson AS, Bhattarchaya T, Haynes BF, Korber BT, Hahn BH, Shaw GM. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206:2869–82.

15. de Roode Husman AM, van Rij RP, Blaak H, Broersen S, Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Exp Med. 1999;180:1106–15.

16. Karlsson I, Grivel J, Chen SS, Karlsson A, Albert J, Fenyo EM, Margolis LB. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. J Virol. 2005;79:11151–60.

17. Vlahakis SR, Algeciras-Schimnich A, Villasis-Keever A, Gomez T, Heppmann CJ, Bou G, Pavy CA. CCR5 mediates Fas- and caspase-8-dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS. 2002;16:1467–78.

18. Wang B. Viral factors in non-progression. Front Immunol. 2013;4:1–7.

19. Dorf G, Cavrinos M, Lassen KG, Zepeda O, Yang Z, Santiago ML, Hbeblere AM, Greene WC. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010;143:789–801.

20. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, Greene WC. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abnormally infected with HIV. Science. 2014;343(6180):428–32.

21. Dorf G, Galloway NLK, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PWT, Harano H, Sovinski S, Muñoz-Arias J, Greene WC. Cell death by pyroptosis drives HIV-1 T cell depletion in HIV-1 infection. Nature. 2013;505:509–14.

22. Tunagurutith PK, Sawabe BE, Singh SP, Tomkowicz B, Ayayoo V, Khalli K, Collman AG, Rominia A, Shirvansana A. Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravasation, intracellular and free Vpr. Biomed Pharmacother. 2003;57:20–4.

23. Muthumani K, Choo AV, Hwang DS, Premkumar A, Dayes NS, Harris C, Green DR, Wadsworth SA, Seeker J, Weiner DB. HIV-1 Nef-induced fast lysis induction and bystander killing requires p38 MAPK activation. Blood. 2005;106:2059–68.

24. Muthumani K, Choo AV, Shedlock DJ, Laddy DJ, Sundaram SG, Hirao L, Wu L, Thieu RP, Chung CW, Lankaram KM, Tebas P, Silvestri G, Weiner DB. Human immunodeficiency virus type 1 Nef induces programmed death-1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol. 2008;82:11356–44.

25. Li CJ, Friedman DJ, Wang C, Metevetel V, Pardee AB. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science. 1995;268:429–31.

26. Santa-Marta M, de Brito PM, Godinho-Santos A, Goncalves J. Host factors and HIV-1 replication: clinical evidence and potential therapeutic approaches. Front Immunol. 2013;4:343.

27. Ovieri K, Scoggins RM, Bor Y, Matthews A, Mark D, Taylor JR, Chennuasik D, Hammarskjöld M-L, Rekosh D, Camerini D. The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. Virology. 2007;358:23–38.

28. Scoggins RM, Taylor JR, Patier J, Ivan't Wout AB, Schuitemaker H, Camerini D. Pathogenesis of primary HIV-1 infection: human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol. 2000;74:3205–15.

29. Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn MS, Brouwer DB, Barbour S, Kovaliev GJ, Unutmaz D, Su L. FoxP3+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2−/−γc−/− mice and in vivo. Blood. 2008;112:2658–68.

30. Gasella CR, Raperap EL, Finkel TH. Vps10 increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing. J Virol. 1999;73:92–100.

31. Jacotet E, Ravagnan L, Druliolle S, Merri F, Vieira HLA, Zamzami N, Costantini P, Druliolle S, Hoebeke J, Briand JP, Tinopoulou T, Duaqgas E, Susa ES, Contie D, Xie ZH, Reed JC, Roques BF, Kooberman G. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med. 2000;191:33–46.

32. Trushin SA, Algeciras-Schimnich A, Stacey R, Bren GD, Warren S, Schneppe LD, Badley AD, Trushin SA, Algeciras-Schimnich A, Vlahakis SR, Bren GD, Warren S, Schneppe LD, Badley AD. Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CCR5. J Immunol. 2007;178:4866–33.

33. Popik W, Pitha PM. Early activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and c-Jun N-terminal kinase in response to binding of simian human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:51–6.
immunodeficiency virus to Jurkat T cells expressing CCR5. Receptor. 1998;217:210–7.
42. Corno M Del, Liu Q, Schols D, Clercq E De, Gessani S, Freedman BD, Collman RG. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin—insensitive chemokine receptor signaling. Blood. 2001;98:2909–16.
43. Li H, Pauza CD. Critical roles for Akt kinase in controlling HIV envelope-mediated depletion of CD4 T cells. Retrovirology. 2013;10:60.
44. Ganju BRK, Dutt P, Wu L, Newman W, Avraham H, Avraham S, Groopman JE. C-C chemokine receptor CCR5 signals via the novel tyrosine kinase RAFTK. Blood. 1998;91:791–7.
45. Vodicka MA, Goh WC, Wu LJ, Rogel ME, Bartz SR, Schweickart VL, Raport CJ, Emerman M. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology. 1997;233:193–8.